+++ Ihre Meinung ist uns wichtig: Wie zufrieden sind Sie mit finanzen.ch? - Hier an unserer Umfrage teilnehmen! +++ -w-
News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
09.09.2019 16:35:00

Amarin: Keep Your Dry Powder Ready

Even though I'm an unabashed bull for Amarin (NASDAQ: AMRN), I've never bought a single share of this promising biotech stock. The reason is that I've been waiting for a specific buying opportunity. Namely, the company's upcoming advisory committee meeting for its prescription omega-3 pill, Vascepa, tentatively scheduled for Nov. 14. The key issue is that Amarin's shares are almost certain to nosedive on the accompanying briefing documents for this regulatory hearing. The options market is exhibiting a healthy level of interest in Amarin's Nov. 15 $9 strike price. Such a massive dip might sound alarmist, but the truth is that most biotech stocks wildly overreact to the Food and Drug Administration's (FDA) briefing docs for keystone products like Vascepa, thereby creating a tremendous buying opportunity for risk-tolerant investors. Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Amarin Corporation PLCShs Sponsored American Deposit.Receipt Repr.1 Shmehr Analysen

Eintrag hinzufügen

Auf und Ab nach Brexit-Deal und Quartalszahlen | BX Swiss TV

Finanzen.net News